Network pharmacology prediction and molecular docking analysis reveal the mechanism of modified Bushen Yiqi formulas on chronic obstructive pulmonary disease.
Wenglam ChoiYueren WuYifan LiJing-Cheng DongPublished in: The journal of gene medicine (2023)
The active components of MBYF, such as quercetin, kaempferol, luteolin, and baicalein, may be the material basis for the treatment of chronic obstructive pulmonary disease. They affect the expression of inflammatory cells and inflammatory factors, protein phosphorylation, and smooth muscle hyperplasia through tumor necrosis factor, interleukin-17, mitogen-activated protein kinase, nuclear factor-kappa B and other signaling pathways.
Keyphrases
- nuclear factor
- molecular docking
- smooth muscle
- toll like receptor
- chronic obstructive pulmonary disease
- induced apoptosis
- oxidative stress
- signaling pathway
- molecular dynamics simulations
- poor prognosis
- protein kinase
- cell cycle arrest
- binding protein
- rheumatoid arthritis
- lung function
- pi k akt
- endoplasmic reticulum stress
- genome wide
- tyrosine kinase
- gene expression
- cell death
- single cell
- inflammatory response
- immune response
- epithelial mesenchymal transition
- protein protein
- combination therapy
- long non coding rna
- cell proliferation